News

NMOSD Diagnosis Without AQP4 Antibodies Requires More Scrutiny

Reaching a neuromyelitis optica spectrum disorder (NMOSD) diagnosis in the absence of disease-causing antibodies requires careful attention from physicians in order to ensure timely treatment. That suggestion comes from a case report of a man in Nepal who had symptoms of the autoimmune disease but lacked the antibodies against…

SinoMab Cleared by China to Test Its Immunosuppressant SN1011

SinoMab BioScience has been cleared by Chinese regulators to launch a clinical trial for its experimental immune-suppressing therapy SN1011 in people with neuromyelitis optica spectrum disorder (NMOSD). The company is anticipating that the Phase 2/3 trial will begin enrolling participants in early 2023. “The IND [investigational new drug]…

NMOSD, MS Tied to Higher Risk for Parkinson’s in South Korea

Patients with neuromyelitis optica spectrum disorder (NMOSD) or multiple sclerosis (MS), another disease that damages the protective myelin sheaths around nerve cells, are at higher risk than healthy individuals of also developing Parkinson’s disease (PD), a South Korean study found. The study, “Risk of Parkinson’s disease…

China OKs Clinical Testing of First CAR T-cell Therapy in NMOSD

Authorities in China have granted IASO Biotherapeutics the go-ahead to begin clinical testing of the experimental CAR T-cell therapy equecabtagene autoleucel in people with neuromyelitis optica spectrum disorder (NMOSD), IASO announced. NMOSD is an autoimmune disorder wherein the body’s immune system launches an inflammatory attack that damages parts…

CoronaVac Leads to Rare Severe Case of NMOSD in Elderly Woman

The CoronaVac vaccine, which contains inactivated SARS-CoV-2, the virus that causes COVID-19, led to a severe case of late-onset neuromyelitis optica spectrum disorder (NMOSD) in a 70-year-old woman. The unique case was described in an article, “Fulminant neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccination: A…